Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flu Vaccination Response in PTEN Hamartoma Tumor Syndrome
NCT03630523Unknown
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2018
- Primary completion
- Jan 2019
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Open-label trial of Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen in influenza (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Hemagglutination inhibition assay titre at 7 days. Status: unknown.
02
Drugs
Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03630523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630523.